FORT COLLINS, CO / ACCESSWIRE / August 25, 2022 / Statera Biopharma, Inc. (NASDAQ:STAB) (the "Company" or "Statera Biopharma"), a biopharmaceutical company creating next-generation immune therapies that
Statera Biopharma Receives Anticipated Notice of Additional Filing Delinquency from Nasdaq newjerseytelegraph.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from newjerseytelegraph.com Daily Mail and Mail on Sunday newspapers.
Statera Biopharma Receives Anticipated Notice of Additional Filing Delinquency from Nasdaq tennesseedaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tennesseedaily.com Daily Mail and Mail on Sunday newspapers.
The global bioterrorism market was valued at $10800 Mn in 2018 and is expected to grow to $17200 Million by 2025, according to a new report by Market.us.
FORT COLLINS, Colo., May 13, 2022 Statera Biopharma , a biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, announced today.